1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

Awaiting development [GID-TA11486] Expected publication date: TBC

  • Project information
  • Project documents

NIHRIO BN: 35842-Pembrolizumab-Favezelimab-for-Hodgkin-Lymphoma-V1.0-NOV2023-NON-CONF.pdf (nihr.ac.uk)